Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019

Clinical characteristics of Japanese patients with moderate to severe COVID-19

(2021) Ryota Otoshi et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Serum KL‐6 concentrations as a novel biomarker of severe COVID19

(2020) Miriana d'Alessandro et al.   JOURNAL OF MEDICAL VIROLOGY

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

(2020) Maximilian Ackermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

(2020) Alfonso J. Rodriguez-Morales et al.   Travel Medicine and Infectious Disease

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

(2020) Sharon E Fox et al.   Lancet Respiratory Medicine

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Serum Krebs von den Lungen‐6 level in the disease progression and treatment of Mycobacterium avium complex lung disease

(2020) Takanori Asakura et al.   RESPIROLOGY

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study

(2020) Thomas M Drake et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer

(2011) Sonosuke Tanaka et al.   INTERNATIONAL JOURNAL OF CANCER